Case todayBrokenLate SEC filing · Nov 18, 2026The case · mixed · Nov 8, 2026Own LTRN if Lantern Pharma is a binary, financing-sensitive bet that its AI-driven oncology platform can produce partner-grade clinical evidence before cash burn forces highly dilutive capital.4 conditions1 strengthening · 1 holding · 2 weakeningNext resultsFeb 17, 2027Projected from its filing dates

LTRN at a glance

The past year

Chart

−91.2% $0.28, close Nov 19

From the highest close
−93.2%
Vs the 200-day average
−87.5%
Nov 18, 2025Daily close, Lantern PharmaNov 19, 2026

Short interest

History

924,479 shares

Of shares outstanding
5.82%
Since the last report
+137.9%
Days to cover
2.7 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 14 – Nov 20

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

LTRN price history

Latest price$0.24Today−$0.04 (-15.85%)
LTRN -64.00%S&P 500 -9.87%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • Lantern’s AI-led oncology model must keep development spending materially leaner than a conventional biotech path while still advancing candidates; otherwise the promised cost-and-speed advantage is not economically real.HoldingMateriality: High

    GAAP annual operating cash flow was -$15.7 million in FY2025 versus -$17.8 million in FY2024, showing cash burn declined year over year. If the platform truly lowers the cost of oncology development, each dollar of capital buys more shots on goal; if not, Lantern is just another cash-burning microcap biotech.

    Watch: Clinical-trial execution, CRO, regulatory, or manufacturing requirements rise faster than the platform can offset as programs move deeper into human studies.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow was -$15.7 million in FY2025 versus -$17.8 million in FY2024, showing cash burn declined year.

    Open source ↗
  • Lantern’s ability to capture value from its pipeline depends on securing capital or partnerships before liquidity dictates program delays, cuts, or highly dilutive equity issuance.WeakeningMateriality: High

    Cash and cash equivalents were $4.4 million at FY2025 year-end, down from $7.5 million at FY2024 year-end and $21.9 million at FY2023 year-end. Financing terms will determine whether clinical upside accrues to current shareholders or is transferred to new investors and partners.

    Watch: Lantern is unable to raise equity on acceptable terms before additional clinical milestones.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash and cash equivalents were $4.4 million at FY2025 year-end, down from $7.5 million at FY2024 year-end and $21.9 million.

    Open source ↗
  • The operating model relies on a very small internal team using the AI platform and outsourced capabilities; if advancing the pipeline requires a conventional large biotech organization, Lantern loses a central economic rationale.StrengtheningMateriality: Medium

    Lantern reported 16 employees as of the 2026 filing date. A lean model preserves option value and reduces dilution; a forced buildout would raise fixed costs before any product revenue exists.

    Watch: Clinical, regulatory, biomarker, manufacturing, or quality-control demands require a major internal hiring ramp.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Lantern reported 16 employees as of the 2026 filing date.

    Open source ↗
  • Lantern needs clinical or partnering validation to replenish enterprise value before cumulative losses shrink the asset base further.WeakeningMateriality: Medium

    Total assets fell to $11.0 million at FY2025 year-end from $25.6 million at FY2024 year-end and $43.6 million at FY2023 year-end. Without validation, the company’s balance sheet erodes while the market has little tangible basis to capitalize the pipeline.

    Watch: Oncology candidates fail to produce human efficacy or safety data strong enough to attract investors, acquirers, or licensing partners.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Total assets fell to $11.0 million at FY2025 year-end from $25.6 million at FY2024 year-end and $43.6 million at FY2023.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Lantern’s AI-led oncology model must keep development spending materially leaner than a conventional biotech path while still advancing candidates; otherwise the promised cost-and-speed advantage is not economically real. If the platform truly lowers the cost of oncology development, each dollar of capital buys more shots on goal; if not, Lantern is just another cash-burning microcap biotech.

Lantern’s ability to capture value from its pipeline depends on securing capital or partnerships before liquidity dictates program delays, cuts, or highly dilutive equity issuance. Financing terms will determine whether clinical upside accrues to current shareholders or is transferred to new investors and partners.

The operating model relies on a very small internal team using the AI platform and outsourced capabilities; if advancing the pipeline requires a conventional large biotech organization, Lantern loses a central economic rationale. A lean model preserves option value and reduces dilution; a forced buildout would raise fixed costs before any product revenue exists.

Lantern needs clinical or partnering validation to replenish enterprise value before cumulative losses shrink the asset base further. Without validation, the company’s balance sheet erodes while the market has little tangible basis to capitalize the pipeline.

All standing thesis claims
Original report summary

Lantern Pharma is a binary, financing-sensitive bet that its AI-driven oncology platform can produce partner-grade clinical evidence before cash burn forces highly dilutive capital.

Evidence assessed Nov 8, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Lantern Pharma

Where the evidence on Lantern Pharma disagrees: Mixed on the latest evidence (Nov 8, 2026). Of its 4 thesis points, 1 strengthening, 1 holding and 2 weakening.

Bull case: what the evidence supports

  • Lantern’s AI-led oncology model must keep development spending materially leaner than a conventional biotech path while still advancing candidates; otherwise the promised cost-and-speed advantage is not economically real.

    sec.gov ↗

  • The operating model relies on a very small internal team using the AI platform and outsourced capabilities; if advancing the pipeline requires a conventional large biotech organization, Lantern loses a central economic rationale.

    sec.gov ↗

Bear case: what the evidence questions

  • Lantern’s ability to capture value from its pipeline depends on securing capital or partnerships before liquidity dictates program delays, cuts, or highly dilutive equity issuance.

    sec.gov ↗

  • Lantern needs clinical or partnering validation to replenish enterprise value before cumulative losses shrink the asset base further.

    sec.gov ↗

Thesis-Break Engine

What has broken in Lantern Pharma’s thesis

Each break OptimistFi flagged on Lantern Pharma, dated — with what has historically followed the same kind of break across the market, not a forecast for Lantern Pharma.

peers+16%-43%-12%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -12% path vs comparable companies over six months, inside the middle-half range (+16% to -43%). A base rate, not a forecast.
  • Late SEC filingcondition set before this filing

    Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Delisting notice or listing-rule failure.

    Lantern Pharma filed an SEC 8-K on 2026-10-01: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.

  2. Mixed
    Entered a material definitive agreement.

    Lantern Pharma filed an SEC 8-K on 2026-09-30: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  3. Mixed
    Regulation FD disclosure.

    Lantern Pharma filed an SEC 8-K on 2026-09-24: Regulation FD disclosure. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Clinical-trial execution, CRO, regulatory, or manufacturing requirements rise faster than the platform can offset as programs move deeper into human studies.
  • Lantern is unable to raise equity on acceptable terms before additional clinical milestones.
  • Clinical, regulatory, biomarker, manufacturing, or quality-control demands require a major internal hiring ramp.
  • Oncology candidates fail to produce human efficacy or safety data strong enough to attract investors, acquirers, or licensing partners.

LTRN news

Loading headlines…

Financial statements

LTRN income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

LTRN: quick answers

When does Lantern Pharma (LTRN) report earnings next?
Lantern Pharma's next results are projected for February 17, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 18, 2026. Earnings calendar
What is LTRN's short interest?
As of October 30, 2026, 924,479 LTRN shares were sold short, 5.82% of its shares outstanding, up 137.9% from the count before. At the stock's average daily volume that is 2.7 days to cover. FINRA publishes the count twice a month. LTRN short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.